RxDoctor Payments DataLook up a doctor →

Robert Malanuk, MD

Interventional Cardiology · West Columbia, SCNPI 1740242304

Payments from drug & device makers

$62,765in general payments, 2019–2025

Across 827 payments — averaging $75.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$29K
  • E.r. Squibb & Sons, L.L.C.$15K
  • Abbott$9K
  • Biotronik Inc.$2K
  • Novartis$1K
  • Amgen$896
  • plus $6K from 41 others

What the payments were for

  • Consulting fees$9004%
  • Speaking & faculty fees$12,35949%
  • Food & beverage$12,08348%
  • Education$640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,765 in reported general payments places this provider in the 80th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$716,415
Medicare patients
2,537
Services billed
9,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,199$1,197,112
EntrestoSacubitril/Valsartan329$344,688
XareltoRivaroxaban147$146,794
Repatha SureclickEvolocumab128$113,774
FarxigaDapagliflozin Propanediol119$98,521
JardianceEmpagliflozin37$46,147
MultaqDronedarone Hcl20$25,848
BrilintaTicagrelor44$19,374
Praluent PenAlirocumab27$19,022
Metoprolol Succinate1,003$16,918
Atorvastatin Calcium847$13,284
Rosuvastatin Calcium391$9,264
Ezetimibe260$9,209
Ranolazine ErRanolazine93$8,263
VascepaIcosapent Ethyl15$7,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$740$1,197,1121,199 claims
NovartisEntresto$1,319$344,688329 claims
Johnson & JohnsonXarelto$235$146,794147 claims
AstraZenecaFarxiga, Brilinta$394$117,896163 claims
Boehringer IngelheimJardiance$191$46,14737 claims
Sanofi-aventis U.S. LLCMultaq$328$25,84820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →